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Abstract
The discovery in mice of a new lineage of CD4+ effector T helper
(Th) cells that selectively produce IL-17 has provided exciting new
insights into immune regulation, host defence, and the patho-
genesis of autoimmune and other chronic inflammatory disorders.
This population of CD4+ Th cells, which has been termed ‘Th17’,
indeed plays an apparently critical role in the pathogenesis of some
murine models of autoimmunity. Interestingly, murine Th17 cells
share a common origin with Foxp3+ T regulatory cells, because
both populations are produced in response to transforming growth
factor-β, but they develop into Th17 cells only when IL-6 is
simultaneously produced. Initial studies in humans have confirmed
the existence of Th17 cells, but they have shown that the origin of
these cells in humans differs from that in mice, with IL-1β and IL-23
being the major cytokines responsible for their development.
Moreover, the presence in the circulation and in various tissues of
Th cells that can produce both IL-17 and interferon-γ, as well as
the flexibility of human Th17 clones to produce interferon-γ in
addition to IL-17 in response to IL-12, suggests that there may be
a developmental relationship between Th17 and Th1 cells, at least
in humans. Resolving this issue has great implications in tems of
establishing the respective pathogenic roles of Th1 and Th17 cells
in autoimmune disorders. In contrast, it is unlikely that Th17 cells
contribute to the pathogenesis of human allergic IgE-mediated
disorders, because IL-4 and IL-25 (a powerful inducer of IL-4) are
both potent inhibitors of Th17 cell development.
Introduction
The adaptive effector CD4+ T helper (Th)-mediated immune
response is highly heterogeneous, based on the development
of distinct subsets that are characterized by various profiles
of cytokine production. Initially, two polarized forms of Th
effectors, namely type 1 (Th1) and type 2 (Th2), were
identified in both mice and humans [1,2]. Th1 cells produce
interferon (IFN)-γ and their primary role is to protect against
intracellular microbes; in contrast, Th2 cells produce IL-4,
IL-5, IL-9 and IL-13 and are involved in protection against
gastrointestinal nematodes, but they are also responsible for
allergic disorders [3,4].
Th1 and Th2 cells develop via activation of various transcription
factors, the most important being signal transducer and
activator of transcription (STAT)-4 and T box expressed in T
cells (T-bet) for Th1 cells, and STAT-6 and GATA-binding
protein (GATA)-3 for Th2 cells [5]. T-bet binds the promoter of
IFN-γ whereas GATA-3 drives epigenetic changes in the Th2
cytokine cluster (IL-4, IL-5 and IL-13), thus giving rise to the
development of Th1 and Th2 cells, respectively [6]. The
mechanisms responsible for the polarization of the naïve Th
cells toward the Th1 or Th2 profile of cytokine production have
not yet been completely clarified. However, early production of
IFN-γ, IFN-α, or IL-12 by cells of the innate immune system
drives Th1 differentiation, whereas early production of IL-4, in
the absence of IL-12, drives Th2 differentiation [3,4]. Natural
killer cells are the major source of IFN-γ, whereas plasmocytoid
dendritic cells (DCs) are the major source of IFN-α [6]. The
most powerful Th1-polarizing cytokine is IL-12 [7], which is
produced by myeloid DCs after triggering of many of their Toll-
like receptors by pathogen products. However, the expression
by DCs of various ligands for the Notch receptors present on
the naïve Th cells appears also to be involved in the
differentiation process. The prevalent expression on DCs of
Jagged favours Th2 polarization, even independently of IL-4
production, whereas expression of Delta ligand triggers Th1
polarization [8]. This latter finding has recently been confirmed,
including in humans. Immature myeloid DCs express Jagged-1,
which triggers a Th2-polarizing programme in CD4+ T cells,
whereas stimulation of Toll-like receptors on DCs upregulates
the Delta-4 ligand, which triggers in the same cells an opposite,
Th1-polarizing programme [9]. In addition, at least in mice, early
IL-4 production by naïve Th cells can also be induced by IL-25,
a cytokine that is produced not only by Th2 cells but also by an
unidentified cell type found in the gut of worm-infested mice
[10] or by lung epithelial cells [11]. A third type of Th cell that
can produce both Th1 and Th2 cytokines, namely type 0 (Th0),
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During the past few years, a novel family of CD4+ Th cells
was detected, which is essentially characterized by IL-17
production and was therefore named ‘Th17’ [13-19]. Th17
cells exist in both mice and humans, but their phenotypic and
functional features, as well as the mechanisms responsible
for their development in the two species, appear to be
different. In this review I describe the main characteristics of
human as compared with murine Th17 cells, and I discuss
their possible roles in protection against infectious agents
and in immunopathology.
Discovery of murine Th17 cells and their origin
Although the existence of IL-17 as a product of activated
CD4+ T cells has been known for more than 10 years, only
recently was the existence of Th17 cells as a distinct subset
recognized [13-19]. The breakthrough leading to the
discovery of the Th17 lineage came from murine models of
autoimmunity. Experimental autoimmune encephalomyelitis
(EAE) and collagen-induced arthritis (CIA) have historically
been associated with unchecked Th1 responses, largely
based on studies in which disease development was ablated
by treatment with neutralizing antibodies specific for
IL-12p40 or gene-targeted mice deficient in the p40 subunit
of IL-12.
The link with IL-12 in these diseases was called into question
by the discovery that a new IL-12 family member, namely
IL-23, shares with IL-12 the p40 subunit, the heterodimer of
IL-12 being composed of p40 and p35, and that of IL-23
being composed of p40 and p19. Therefore, an elegant
series of studies was conducted that showed that EAE and
CIA did not develop in mice deficient in IL-23p19 subunit,
whereas they could develop in those deficient in IL-12p35
subunit [13,14]. This suggests that IL-23, but not IL-12, is
critically linked to autoimmunity, at least in these models.
Moreover, a positive correlation was established between the
availability of IL-23 and IL-17 producing effector T cells and
disease development, and a negative correlation was
established between IL-12 and IFN-γ producing Th1 cells and
disease development [20]. Subsequent studies demon-
strated that although IL-12 polarized cells (prototypic Th1
cells) expressed genes associated with cytotoxicity, such as
those encoding IFN-γ, Fas ligand and granzymes, IL-23
polarized cells expressed genes associated with chronic
inflammation, such as IL-17, IL-17F, IL-6, tumour necrosis
factor-α and proinflammatory chemokines. Based on these
findings, a new role for Th17 cells in immunopathology and
the distinct origin of Th1 and Th17 cells under differential
IL-12 or IL-23 conditioning was proposed [16]. According to
this model, early differentiation of Th1 and Th17 cells from
naïve CD4+ T-cell precursors was shared, and thus Th1 and
Th17 diverged contingent upon selective availability of IL-12
and IL-23 acting on a common ‘Th1 precursor’ or ‘pre-Th1
intermediate’ that co-expressed both IL-12 and IL-23
receptors [21,22].
More recently, however, a completely different model of
murine Th17 development has been described. Although
IL-23 appeared to be required for Th17-mediated immuno-
pathology, different reports indicated that IL-23 was not
critical for Th17 commitment, but only appeared to be
required to amplify and/or stabilize the Th17 phenotype [17].
More importantly, three different groups independently
demonstrated that transforming growth factor (TGF)-β was
required for initiation and that IL-6 was a critical co-factor for
Th17 differentiation (Figure 1). IL-1β and tumour necrosis
factor-α were also found to amplify the Th17 response
induced by TGF-β and IL-6, but they could not substitute for
either of these cytokines [23-25]. More recently, it was shown
that IL-21, a cytokine produced by Th17 cells themselves,
provides an additional autocrine amplificatory signal (Figure 1)
[26,27]. Of note, the Th17 polarizing cytokine TGF-β was
already known for its ability to promote the development of
Foxp3+ T regulatory (Treg) cells. However, expression of
IL-17 or Foxp3 was restricted to separate subsets, so that
TGF-β driven Th17 and Treg development from naïve pre-
cursors appeared to be mutually exclusive. Importantly, in the
presence of IL-6, TGF-β induced development of Treg cells
was blocked, whereas blockade of IL-6 permitted develop-
ment of Foxp3+ Treg cells, suggesting that IL-6 inhibited Treg
development while enhancing Th17 development induced by
TGF-β [17,24,25]. In a recent study, however, an IL-6
independent pathway of murine Th17 differentiation has been
discovered [28].
Properties of murine Th17 cells and their role
in protection and immunopathology
The master regulator that directs the differentiation program
of Th17 cells is the orphan retinoid nuclear receptor (ROR)γt,
whereas neither GATA-3 nor T-bet are required for this
function [29]. More recently, it was found that Th17 cells
express high levels of another related nuclear receptor,
namely RORα, induced by TGF-β and IL-6, which is
dependent on STAT-3 [30].
The major functions of cytokines produced by Th17 cells is to
chemoattract different cell types through induction of other
cytokines and chemokines. Both IL-17 (or IL-17A) and IL-17F
act on a broad range of cell types to induce the expression of
cytokines (such as IL-6, granulocyte/macrophage colony-
stimulatory factor and granulocyte colony-stimulatory factor)
and chemokines (such as IL-8, CXC chemokine ligand 1 and
10, and CC chemokine ligand 20), as well as metallo-
proteinases (Figure 2). Therefore, both IL-17 and IL-17F are
key cytokines for the recruitment, activation and migration of
neutrophils. Th17 cells also produce IL-21, which is a
powerful B-cell differentiating factor [31], but it also plays an
important autocrine amplifying role on Th17 responses
[26,27] (see above). Th17 cells also produce IL-22, which is
a member of the IL-10 family that has been found to be
strongly upregulated during chronic inflammatory disorders
and can induce acantosis and dermal inflammation [32].Page 3 of 8
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However, in other tissues, such as liver, IL-22 has been
shown to counteract the destructive nature of the inflam-
matory response, thus playing a protective role [33]. Finally,
Th17 cells produce IL-26 [34], whose exact role in the Th17
response is not yet established (Figure 2). Murine Th17 cells
are subjected to strict control by several cytokines (Figure 1).
The development of these cells is indeed inhibited under Th1
or Th2 polarizing conditions, which means that IL-12, IFN-γ
and IL-4 play negative regulatory roles in the development of
Th17 cells [6]. Even IL-2 has a negative effect on the Th17
differentiation [35]. More recently, IL-25 and IL-27 were also
found to inhibit Th17 cells [36,37]. Of note, IL-25 is an
inducer of IL-4 [9,10] whereas IL-27 is a potent inducer of
IL-10 in CD4+ T cells [38,39] and allows the development of
Th1 cells [40].
Because of their functional properties, Th17 cells have been
suggested to play an important role in responses against
extracellular Gram-negative bacteria and fungi, in which
granulocyte infiltration is highly protective (Figure 2). Accor-
dingly, preferential IL-17 production by T cells has been
found during infection with Klebsiella pneumoniae,
Bacteroides fragilis, Citrobacter rodentium, Escherichia coli,
Borrelia burgdoferi and fungal species, whereas IL-17
appears to play a modest role (if any) in protecting against
intracellular mycobacteria [41]. Notably, however, high fungal
burden was found to counter-regulate IL-12 production and
to induce production of both IL-23 and IL-17, which
subverted the inflammatory program of neutrophils, thus
resulting in severe tissue inflammatory pathology rather than
protection [42].
In addition to infections, Th17 cells play an important role in
the induction and propagation of autoimmunity in various
animal models (Figure 2). IL-17 deficient mice or mice treated
with an IL-17 receptor antagonist are resistant to
development of CIA and develop EAE with delayed onset and
reduced severity [16,43]. Furthermore, administration of an
IL-17 blocking antibody in mice immunized with a myelin
antigen prevents chemokine expression in the brain and the
subsequent development of EAE [44]. These data support
the idea that IL-17 is involved in the pathogenesis of several
autoimmune diseases in mice and possibly also in humans. In
this context, the presence, and sometimes the prevalence, of
Th1 cells in the inflammatory tissues of murine autoimmune
disorders has been interpreted as a protective, rather than
proinflammatory, mechanism, based on the following observa-
tions: IFN-γ or IFN-γ receptor deficient mice are still
susceptible to EAE and CIA [45,46]; and IFN-γ inhibits
development of Th17 cells [6]. However, other authors do not
agree with this conclusion. First, T-bet has been found also to
be required for optimal IL-17 production in the presence of
IL-23 [47]. Second, therapeutic administration of small
interfering RNA specific for T-bet significantly improved the
Available online http://arthritis-research.com/content/10/2/206
Figure 1
Pathway of murine Th17 differentiation. IL-17 producing CD4+ T
helper (Th17) cells originate in response to transforming growth factor
(TGF)-β and IL-6 produced by dencritic cells (DCs), whereas TGF-β
alone in the absence of IL-6 promotes differentiation of the naïve
T helper (Th) cell into a Foxp3+ T regulatory (Treg) cell. IL-23 produced
by DCs allows the expansion and/or survival of Th17 cells. Th17 cells
themselves produce IL-21, which provides an autocrine amplification
loop. IFN-γ, IL-4, IL-25 and IL-27 play an inhibitory role in the
development of murine Th17 cells. Double parallel lines across the
arrow mean inhibitory effect. ROR, orphan retinoid nuclear receptor.
Figure 2
Main activities attributed to Th17 cells. IL-17 producing CD4+ T helper
(Th17) cells produce several cytokines, the most important being IL-17
or IL-17A, which activated multiple cell types to produce proinflammatory
cytokines, chemokines, nitric oxide synthase (NOS)-2, metallo-
proteinases (matrix metalloproteinase [MMP]3) and colony-stimulating
factor. This results in granulocyte recruitment, which plays an important
role in protection against extracellular bacteria but also in macrophage
recruitment and establishment of chronic inflammation. CCL, CC
chemokine ligand; CXCL, CXC chemokine ligand; G-CSF, granulocyte
colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-
stimulating factor; Th, T helper; TNF, tumour necrosis factor.clinical course of established EAE by limiting the
differentiation of autoreactive Th1 cells and inhibiting
pathogenic Th17 cells through regulation of IL-23 receptor
[48]. Third, in Helicobacter induced colitis, IFN-γ but not
IL-17 was the crucial T cell effector cytokine when Treg cells
were absent [49]. Fourth, using T cell specific TGF-β
deficient mice, the major pathogenic population generated
during the establishment of colitis was Th1 cells [50]. Fifth,
even in mice with EAE, acquisition of pathogenic function by
effector Th17 cells was found to be mediated by IL-23 rather
than by TGF-β and IL-6 [51]. Finally, an impressive series of
previous observations clearly demonstrated a pathogenic,
rather than protective, role of IFN-γ in various murine models
of autoimmune disorders [52-60]. Hence, even in murine
models, several lines of evidence suggest that Th1 cells can
contribute to the inflammatory process rather than simply
protecting tissues from Th17-driven inflammation.
Phenotypic and functional features of human
Th17 cells
Recent systemic studies have been performed to identify
Th17 cells in humans and to characterize their phenotype and
functions. Two independent studies have demonstrated the
existence of CD4+ memory T cells producing IL-17 after poly-
clonal stimulation in human peripheral blood and in gut from
healthy individuals or patients with Crohn’s disease [61,62].
Both studies revealed the presence in these cells of RORγt,
IL-23 receptor and the CC chemokine receptor 6, whereas
they lacked CXC chemokine receptor 3, a chemokine
receptor that is usually espressed by Th1 cells. Moreover,
one of the studies identified possible specificity for Candida
albicans hyphae of T cells producing IL-17. In the other study
various functional features of human Th17 cells were
assessed, including at the clonal level [62]. Human Th17
cells exhibited poor proliferative capacity and cytotoxic
potential; could induce the production by B lymphocytes of
IgG, IgM and IgA, but not IgE; and appeared to be less
susceptible than Th1 or Th2 clones to the suppressive
activity of an autologous Foxp3+ Treg clone. Moreover, some
differences between the two studies were also observed. For
example, we identified the existence of a remarkable number
of either double positive (IFN-γ+IL-17+) freshly derived cells or
T-cell clones (that we named ‘Th17/Th1’), a finding that has
also been reported, but not sufficiently stressed, in mouse
studies. In contrast, in our study clones producing both IL-17
and IL-4 were not observed [62]. More importantly, we found
that both classic Th17 and Th17/Th1 clones consistently
exhibited not only expression of RORγt but also that of T-bet,
at both mRNA and protein levels [62]. The incubation of Th17
clones with IL-12 allowed these cells to produce IFN-γ in
addition to IL-17, and this effect was associated with reduced
RORγt and increased T-bet expression. Notably, the IL-12
mediated effects were partially inhibited in the presence of
IL-23, suggesting the existence of a flexibility between Th17
and Th1 cells and a possible developmental relationship
between the two cell types [62].
Induction and regulation of Th17 cells in
humans
More recent studies, although partially contradictory, have
clearly shown that the induction of Th17 cells in humans is
completely different from that in mice. Acosta-Rodriguez and
coworkers [63] reported an essential role for IL-1β, in
addition to IL-6, but no activity in response to TGF-β in
promoting differentiation of naïve CD4+ T cells into Th17
cells. Chen and colleagues [64] found that both IL-6 and
TGF-β upregulated RORγt expression, but they did not
induce Th17 differentiation in human naïve T cells.
Conversely, IL-23 promoted the generation of human Th17
cells but was also an important inducer of other pro-
inflammatory cytokines. Wilson and coworkers [65] found
that either IL-1β or IL-23 alone was sufficient to induce
development of IL-17 producing cells. Finally, van Beelen and
colleagues [66] demonstrated that human Th17 cells could
be derived only by memory, and not by naïve, T cells, and this
effect was due to the nucleotide oligomerization domain 2
ligand muramylpeptide, which enhanced IL-23 and IL-1
production by DCs.
Thus, in contrast to the findings reported in mice, all of these
studies agreed that TGF-β was not essential for or inhibited
the development of human Th17 cells [63-66]. However,
these studies were performed using CD45RA+ T cells purified
from peripheral blood of adults. Hence, the possibility
remains that the procedure of purification of CD45RA+
T cells could have resulted in contamination of the culture
with memory CD4+ T cells, thus affecting the results [67]. To
circumvent this problem, we investigated the mechanisms
responsible for the differentiation of human Th17 cells using
purified CD4+ T cells obtained from umbilical cord blood. In
our system, either IL-1β or IL-23 upregulated the expression
of both IL-23 receptor and RORγt, and IFN-γ, but only the
combination of the two cytokines allowed CD4+ T cells to
express and produce IL-17. Again, we observed the
development not only of Th17 but also of Th17/Th1 cells.
Moreover, although the addition of IL-4 to the mixture of IL-1
and IL-23 consistently inhibited the expression of IL-23
receptor, RORγt and IL-17, the addition of IL-12 reduced the
expression of IL-17 without affecting Th17/Th1 cells.
Moreover, TGF-β did not affect either RORγt or the IL-23
receptor, but virtually abolished T-bet expression, thus
reducing Th1 and Th17/Th1 while increasing Th17 cells
(unpublished data).
Taken together, these data support the difference in origin of
Th17 cells between mice and humans, and once again
suggest the existence of a developmental relationship
between human Th17 and Th1 cells (Figure 3).
Possible role of Th17 cells in human
immunopathology
Because of differences in some properties and in the
mechanism of origin between murine and human Th17 cells,
Arthritis Research & Therapy    Vol 10 No 2 Romagnani
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the CD4+ T cell effector family in the pathogenesis of human
disorders; furthermore, this difficulty is exacerbated by the
paucity of information currently available.
A greater number of IL-17 mRNA expressing cells were found
by using in situ hybridization in cerebrospinal fluid than in
peripheral blood from patients with multiple sclerosis [68].
More importantly, human Th17 lymphocytes have been found
to promote blood-brain barrier disruption and central nervous
system inflammation through CD4+ lymphocyte recruitment
[69]. Moreover, both IL-17 and IL-23p19 were found in sera,
synovial fluid, and synovial biopsies of most patients with
rheumatoid arthritis (RA), whereas both of them were absent
in osteoarthritis [70,71]. IL-17 has also been detected in the
sera and diseased tissues of patients with systemic lupus
erythematosus [72] or systemic sclerosis [73]. Recently,
increased expression of CC chemokine ligand 20 (the
chemokine able to bind CC chemokine receptor 6 expressing
Th17 cells [61,62]) in the inflamed joints of patients with RA
has been reported [74]. High IL-17 levels have also been
found in the sera and colonic biopsies of patients with
Crohn’s disease [75,76], in whom IL-17F appears to play an
important role [77], as well as in the affected skin of patients
with inflammatory skin disorders such as nickel-induced
dermatitis, psoriasis and atopic dermatitis [78,79]. However,
the great majority of these studies were performed by
assessing the presence of mRNA for IL-17 in tissues and/or
measuring IL-17 protein in biologic fluids. Moreover, some of
these findings were recently challenged. For example, in a
recent study the frequency of Th17 cells was significantly
decreased in the joints a compared with peripheral blood
from the same RA patients, whereas Th1 cells were more
abundant in the joints than in peripheral blood [80]. Thus, the
role played by Th17 cells in the pathogenesis of human
autoimmune disorders, although very probable, is not yet
proven. More importantly, the respective roles of Th17 and
Th1 cells in inflammatory sites remain unclear; the solution of
this problem rests mainly on the demonstration of whether (at
least in humans) a developmental relationship between the
two cell types does indeed exist.
With regard to the possible pathogenic role of Th17 cells in
allergic disorders, it has been claimed that these cells may
play a critical role in the granulocyte infiltration that is present
in the bronchi of some asthmatic patients [81]. Obviously,
because Th17 cells have a particular ability to recruite
granulocytes, it cannot be excluded that IL-17 recruited cells
can enhance bronchial inflammation in severe asthma
complicated by bacterial infections. However, it is highly
unlikely that Th17 plays a role in classic IgE-mediated allergic
disorders. First, Th17 cells can induce production of IgM, IgG
and IgA antibodies, but not IgE antibodies [62]. Second, the
presence of IL-4 is among the most effective inhibitory signals
for the differentiation of Th17 cells in both mice [6] and
humans  [63-66] (unpublished data). Finally, we recently
examined the phenotype of T cell clones specific for amoxicillin,
which were generated from the peripheral blood of a patient
who had suffered an amoxicillin-induced anaphylactic shock
and exhibited amoxicillin-specific IgE antibodies in his serum.
All T cell clones specific for amoxicillin derived from this
patient had a classic Th2 profile and none of them was able
to produce IL-17 (unpublished data), supporting the view that
Th17 cells do not play any role in uncomplicated, IgE-
mediated allergic disorders.
Conclusion
The discovery in both mice and humans of a new member of
the CD4+ effector T-cell family (Th17 cells) has provided
exciting and novel insights into the immune mechanisms that
are responsible for protection and immunopathology. However,
some critical differences appear to exist with regard to the
mechanisms that are involved in the differentiation of murine
and human Th17 cells, which render it difficult to establish
new therapeutic procedures to target these cells or the
cytokines that are responsible for their development. In
particular, in murine experimental models of autoimmunity
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Figure 3
Pathway of human Th17 differentiation. IL-17 producing CD4+ T helper
(Th17) cells originate in presence of IL-23 and IL-1β, each of which
upregulates orphan retinoid nuclear receptor (ROR)γt, T box expressed
in T cells (T-bet), IL-23 receptor (IL-23R) and IL-12 receptor (IL-12R)
in the naïve T hlper (Th) cell. When the two cytokines are produced in
combination, IL-17 mRNA is also expressed and IL-17 is produced
alone or in combination with IFN-γ. The presence of IL-12, in absence
of IL-1β and IL-23, shifts the differentiation of the naïve Th cell toward
the Th1 phenotype. IL-4, which is produced by the Th naïve cell itself
following interaction of its Notch receptors with Jagged-1 expressed
on the dendritic cell (DC) and/or by the presence of IL-25 (still unclear
in humans), has a potent inhibitory effect on the expression of RORγt,
T-bet, IL-23R, IL-12R, IFN-γ, and IL-17. Transforming growth factor
(TGF)-β strongly inhibits the development of both Th1 and Th2 cells,
whereas it has little or no effect on the development of Th17, thus
indirectly favouring their expansion. Double parallel lines across the
arrows mean inhibitory effect.Th17 cells share their origin with Treg cells and are patho-
genic, whereas Th1 cells appear to play a protective role in
response to them. More importantly, that inhibition of Th17
cells favours development of the Treg cell population
represents a source of considerable confusion, with respect
to possible therapeutic options targeting Th17 cells. In
contrast, Th17 cells appear to have a different origin in
humans than in mice, and whether classic Th1 cells play a
protective role against the pathogenic activity of Th17 cells or
contribute alongside them to the pathogenesis of
autoimmune disorders remains unclear. If we are to resolve
this issue, we must determine whether human Th17 cells are
developmentally related to Th1 cells. This represents another
impressive example of how murine models, although
extremely useful, cannot dogmatically be regarded as optimal
models for the development of novel immunotherapeutic
strategies in humans.
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